The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

Trinasolar has received an International Design Excellence Award in the US, within the C&I product category, for its Vertex ...

Some people of West African of descent face a higher risk of renal failure. New drugs based on gene research may help right ...

One is that, also in our pain franchise ... And we intend to fully develop both of these markets at Vertex. We see them both as specialty markets. And longer-term, given the mechanism of action, we ...

Haystack, a leading modern intranet provider, today announced its collaboration with Google Cloud to integrate Google Cloud’s ...

Sometimes, complex technical achievements are best explained through one example. That's the approach Mete Atamel, Developer ...